oral semaglutide dose for obesity Dose-equivalence reference based on pivotal GLP-1/dual-agonist trials: SURMOUNT-1 (tirzepatide/Zepbound, 72 weeks) STEP-1 (subcutaneous semaglutide/Wegovy, 68 weeks) OASIS-4 (oral semaglutide/Wegovy, 64 weeks). educational comparison only—these are What is the equivalent dose

After professional treatments such as peels, microneedling, laser, or micro-infusion, the skin undergoes a controlled micro-injury process that requires regeneration

*Correspondence: Liu Yang, [email protected] These authors have contributed equally to this work Disclaimer All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers

Wegovy is currently the only semaglutide approved specifically for weight loss

The peptide accelerates healing across a range of wound types, including surgical incisions, chronic ulcers, and traumatic injuries, with time reductions of 30-50% reported in multiple studies